Downsizing of Rectal Cancer Following Neoadjuvant Radiotherapy (5 × 5 Gy) and Long Interval Surgery Evaluated Using MRI Semiautomated Volumetric Measurements, a Retrospective Study

IntroductionNeoadjuvant conventional chemoradiation (CRT) is the standard treatment for primary locally non-curatively resectable rectal cancer, as tumor downsizing may allow R0 resectability. Short-term neoadjuvant radiotherapy (5x5 Gy) followed by an interval before surgery (SRT- delay) is an alternative for multimorbid patients who cannot tolerate CRT. This study examined the extent of tumor downsizing achieved with the SRT-delay approach in a limited cohort that underwent complete re-staging before surgery.MethodsBetween March 2018 and July 2021, 26 patients with locally advanced primary adenocarcinoma (>uT3 or/and N+) of the rectum were treated with SRT-delay. 22 patients underwent initial staging and complete re-staging (CT, endoscopy, MRI). Tumor downsizing was assessed by staging and re-staging data and pathologic findings. Semiautomated measurement of tumor volume was performed using mint Lesion™ 1.8 software to evaluate tumor regression.ResultsThe mean tumor diameter determined on sagittal T2 MRI images decreased significantly from 54.1 (23–78) mm at initial staging to 37.9 (18–65) mm at re-staging before surgery (p <0.001) and to 25.5 (7–58) mm at pathologic examination (p <0.001). This corresponds to a mean reduction in tumor diameter of 28.9 (4.3–60.7) % at re-staging and 51.1 (8.7–86.5) % at pathology. Mean tumor volume determined from transverse T2 MR images mint LesionTM 1.8 software significantly decreased from 27.5 (9.8 – 89.6) cm3 at initial staging to 13.1 (3.7 – 32.8) cm3 at re-staging (p <0.001), corresponding to a mean reduction of 50.8 (21.6 – 77) %. The frequency of positive circumferential resection margin (CRM) (less than 1mm) decreased from 45,5 % (10 patients) at initial staging to 18,2 % (4 patients) at re-staging. On pathologic examination, the CRM was negative in all cases. However, multivisceral resection for T4 tumors was required in 2 patients (9%). Tumor downstaging was noted in 15 of 22 patients after SRT-delay.ConclusionIn conclusion, the observed extent of downsizing is broadly comparable to the results of CRT, making SRT-delay a serious alternative for patients who cannot tolerate chemotherapy.